Flyer

nova
DISCOVERY

The future of clinical trials

Increasing trial success rate with **clinical trial simulation**

Nova's mission is to support better clinical development of new drugs matching them with optimal responding patients. Using the jinkō platform, clinical trials are simulated with a computational model of the disease of interest and virtual patients of any specific context or geography.



Jinkō delivers solutions from preclinical to market access

Preclinical development

- Support decision to enter clinical development

Clinical development

- Increase probability of success & reduce ethical and financial costs of human trials
- Augment evidence generation & reduce time to trial completion with virtual patients

Post approval

- Demonstrate value to payers

Our platform and library of disease models give a unique competitive advantage to users to get insights needed to optimize trial protocols (dose, combination of treatments, regiment, inclusion/exclusion criteria - best responders) by testing an unlimited number of designs on an unlimited number of virtual patients. In doing so, our users maximize the odds of a successful trial.

Main advantages of clinical trial simulation

01 Optimize trial design and patient selection

02 Reduce costs

03 Reduce sample size

04 Accelerate clinical development timelines

05 Address ethical concerns

06 Solve data & evidence gaps



Modeling and simulation of clinical trials has become a key strategic approach for optimizing clinical development. Adoption has picked up pace in recent years driven both by highly favorable economics and by the FDA, which received a congressional mandate in to promote in silico approaches.

In silico clinical trial simulations use the same protocol and conditions as the corresponding in vivo trial, and use the same biomarkers and outcomes with the benefit of being able to explore additional modifications and endpoints.

When compared with traditional clinical development, participants in the FDA's Model-Informed Drug Development Pilot Program note significant savings both in time - up to 2 years - as well as in cost -up to $70 million*.

US FDA selected NOVA for the MIDD Pilot Program in 2019 to present its approach to model design and validation.

FDA U.S. FOOD & DRUG ADMINISTRATION

MKT-0003 Rev.D